A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT

Study acronym: TP53
StatusActive, Not Recruiting
PhasePhase 1/2
SponsorLiping Dou
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To explore the safety and efficacy of selinexor combined with azacitidine as post-transplant maintenance therapy for TP53-mutated AML/MDS.
Trial Details
NCT Number NCT07779031
Lead Sponsor Liping Dou
Conditions
(from sponsor)		 Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)
Related terms Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov